Literature DB >> 19556337

Allergic reactions to oxaliplatin in a single institute in Japan.

Yasushi Ichikawa1, Ayumu Goto, Satoru Hirokawa, Miyuki Kijima, Takashi Ishikawa, Takashi Chishima, Hirokazu Suwa, Harumi Yamamoto, Shigeru Yamagishi, Shunichi Osada, Mitsuyoshi Ota, Shoichi Fujii.   

Abstract

Allergic reactions to oxaliplatin can be severe and are an important cause of discontinuation of treatment. A retrospective review was performed for 105 patients who received FOLFOX regimens between May 2005 and June 2007. Twenty-five cases (23.8%) of allergic reactions were identified, including 9 late onset reactions (8.6%) and 16 immediate reactions (15.2%). Severe allergy (Grades 3 and 4) occurred in seven patients (6.7%). Re-introduction of FOLFOX was attempted for seven immediate onset patients with a severity grade of 1 or 2, and three of these patients (42.9%) showed relapse of allergy. In approximately 10% of the patients, FOLFOX had to be discontinued due to allergy before the disease became refractory to the regimen. Our experience indicates that allergy to oxaliplatin may be a significant concern and that methods are required for suppression of this allergy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556337     DOI: 10.1093/jjco/hyp070

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study.

Authors:  Sirinoot Palapinyo; Jettanong Klaewsongkram; Virote Sriuranpong; Nutthada Areepium
Journal:  Pharm Pract (Granada)       Date:  2022-03-31

2.  Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.

Authors:  Qiuyan Song; Yuanxuan Cai; Kangyuan Guo; Min Li; Zaoqin Yu; Qirui Tai; Yuhang Zhao; Xuan Zhu; Chengliang Zhang
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

3.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20

Review 4.  Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer.

Authors:  Xue Song; Stacey R Long; Beth Barber; Cheryl A Kassed; Marcus Healey; Clare Jones; Zhongyun Zhao
Journal:  Curr Clin Pharmacol       Date:  2012-02-01

5.  Hypersensitivity to oxaliplatin: clinical features and risk factors.

Authors:  Marie Parel; Florence Ranchon; Audrey Nosbaum; Benoit You; Nicolas Vantard; Vérane Schwiertz; Chloé Gourc; Noémie Gauthier; Marie-Gabrielle Guedat; Sophie He; Eléna Kiouris; Céline Alloux; Thierry Vial; Véronique Trillet-Lenoir; Gilles Freyer; Frédéric Berard; Catherine Rioufol
Journal:  BMC Pharmacol Toxicol       Date:  2014-01-13       Impact factor: 2.483

6.  Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.

Authors:  Hideki Ohta; Takahiro Hayashi; Sumie Murai; Hideyo Shiouchi; Yosuke Ando; Satomi Kumazawa; Kaori Ito; Yoshiaki Ikeda; Hiroshi Matsuoka; Kotaro Maeda; Kenji Kawada; Kimio Yasuda; Shigeki Yamada
Journal:  Cancer Chemother Pharmacol       Date:  2017-04-08       Impact factor: 3.333

Review 7.  Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review.

Authors:  Anthony Stack; Rashmi Khanal; Crystal S Denlinger
Journal:  Clin Colorectal Cancer       Date:  2020-07-30       Impact factor: 4.481

8.  A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.

Authors:  Yoichiro Yoshida; Keiji Hirata; Hiroshi Matsuoka; Shigeyoshi Iwamoto; Masahito Kotaka; Hideto Fujita; Naoya Aisu; Seiichiro Hoshino; Takeo Kosaka; Kotaro Maeda; Fumiaki Kiyomi; Yuichi Yamashita
Journal:  Drug Des Devel Ther       Date:  2015-11-11       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.